Dalrada Health

cerVIA™: A Cervical Cancer Screening Validation Tool

The visual inspection with acetic acid (VIA) screening test holds the potential to make a positive impact on Cervical cancer health initiatives worldwide. VIA is a recommended course of action for the immediate detection of Cervical cancer, especially in developing countries with limited medical resources. In order to improve for Cervical cancer survivability rates for current and future generations of women around the world, affordable diagnostic alternatives like VIA must be made available.

Dalrada Health’s cerVIA Test Kit™ amplifies & empowers Cervical cancer initiatives worldwide.

cerVIA TEST KIT™ ACCELERATES CERVICAL CANCER SCREENING 

Dalrada Health’s cerVIA Test Kit™ includes 5% acetic acid. Acetic acid is the organic compound that gives vinegar its taste and pungent smell. And when applied topically by a trained healthcare professional in a clinical setting, skin cells that turn white indicate the presence of cervical pre-cancerous or cancerous lesions; this is a VIA-positive result. At the point of procedure, appropriate treatment plans can occur.

VIA/VILI – Visual inspection using Lugol’s iodine (VILI) can be used, following a VIA-positive result. Lugol’s iodine reacts with mature tissue cells containing glycogen; normal skin cells appear brown or black. Low glycogen concentration (pre-cancerous lesions) turns skin cells yellow. Pre-cancerous lesions or cancer are considered pathological and require treatment.

VIA/HPV DNA – A molecular test determines if a patient is at high risk for cervical cancer that can create possible pregnancy complications or pre-term deliveries. If HPV-positive, a VIA test then immediately detects the presence or absence of pre-cancerous and cancerous tissue. HPV-positive women require frequent screening. Molecular tests take up to three weeks for results and are not available worldwide.

 VIA/PAP – The Pap screening method requires laboratory analysis and takes up to three weeks for results. Cytology retests are often needed. Even under optimal conditions, cytology tests have limited results. If a cytology test is positive, a VIA test can actually help validate the results.

cerVIA Test Kit™ screens for Cervical cancer and is versatile and available to women in all countries.
CLINICALLY-PROVEN SCREENING

Cervical cancer screening clinical trials conducted in India reveal that Dalrada Health’s cerVIA Test Kit™ surpasses the capabilities of traditional (Pap) cytology tests. It’s important to note that other countries were able to reduce Cervical cancer incidents by more than 50% by using cytology tests. However, this is not an affordable or available healthcare resource for developing countries that typically lack pathologists and advanced healthcare analysis equipment.

The cerVIA Test Kit™ is an affordable and immediately-available solution for healthcare systems in low-resource countries. As described by the World Health Organization’s recommended practices, this kit can fulfill a vital role as a standardized Cervical cancer screening kit for fast, consistent results. Other main points include:

QUALITY CONTROL: Ensures consistent validation with standardized components sourced from FDA or ISO-approved facilities.

 TIMESAVING: Immediate detection of Cervical cancer at the time of the procedure.

VALIDATION:  Visually confirms high-risk HPV, cytology, and molecular screening results.

To learn more about Dalrada Health Products’ safe, reliable, single-use disposable cerVIA Test Kit™, please visit https://dalradahealth.com/products/cervia-test-kit/.

divider

DALRADA
LATEST NEWS

cerVIA™: A Cervical Cancer Screening Validation Tool

The visual inspection with acetic acid (VIA) screening test holds the potential to make a positive impact on Cervical cancer health initiatives worldwide. VIA is a recommended course of action for the immediate detection of Cervical cancer, especially in developing countries with limited medical resources. In order to improve for Cervical cancer survivability rates for current and future generations of women around the world, affordable diagnostic alternatives like VIA must be made available.

Dalrada Health’s cerVIA Test Kit™ amplifies & empowers Cervical cancer initiatives worldwide.

cerVIA TEST KIT™ ACCELERATES CERVICAL CANCER SCREENING 

Dalrada Health’s cerVIA Test Kit™ includes 5% acetic acid. Acetic acid is the organic compound that gives vinegar its taste and pungent smell. And when applied topically by a trained healthcare professional in a clinical setting, skin cells that turn white indicate the presence of cervical pre-cancerous or cancerous lesions; this is a VIA-positive result. At the point of procedure, appropriate treatment plans can occur.

VIA/VILI – Visual inspection using Lugol’s iodine (VILI) can be used, following a VIA-positive result. Lugol’s iodine reacts with mature tissue cells containing glycogen; normal skin cells appear brown or black. Low glycogen concentration (pre-cancerous lesions) turns skin cells yellow. Pre-cancerous lesions or cancer are considered pathological and require treatment.

VIA/HPV DNA – A molecular test determines if a patient is at high risk for cervical cancer that can create possible pregnancy complications or pre-term deliveries. If HPV-positive, a VIA test then immediately detects the presence or absence of pre-cancerous and cancerous tissue. HPV-positive women require frequent screening. Molecular tests take up to three weeks for results and are not available worldwide.

 VIA/PAP – The Pap screening method requires laboratory analysis and takes up to three weeks for results. Cytology retests are often needed. Even under optimal conditions, cytology tests have limited results. If a cytology test is positive, a VIA test can actually help validate the results.

cerVIA Test Kit™ screens for Cervical cancer and is versatile and available to women in all countries.
CLINICALLY-PROVEN SCREENING

Cervical cancer screening clinical trials conducted in India reveal that Dalrada Health’s cerVIA Test Kit™ surpasses the capabilities of traditional (Pap) cytology tests. It’s important to note that other countries were able to reduce Cervical cancer incidents by more than 50% by using cytology tests. However, this is not an affordable or available healthcare resource for developing countries that typically lack pathologists and advanced healthcare analysis equipment.

The cerVIA Test Kit™ is an affordable and immediately-available solution for healthcare systems in low-resource countries. As described by the World Health Organization’s recommended practices, this kit can fulfill a vital role as a standardized Cervical cancer screening kit for fast, consistent results. Other main points include:

QUALITY CONTROL: Ensures consistent validation with standardized components sourced from FDA or ISO-approved facilities.

 TIMESAVING: Immediate detection of Cervical cancer at the time of the procedure.

VALIDATION:  Visually confirms high-risk HPV, cytology, and molecular screening results.

To learn more about Dalrada Health Products’ safe, reliable, single-use disposable cerVIA Test Kit™, please visit https://dalradahealth.com/products/cervia-test-kit/.

divider

DALRADA
LATEST NEWS

Skip to content